183 related articles for article (PubMed ID: 23000905)
21. Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy.
Koch M; Freundl AJ; Agaimy A; Kiesewetter F; Künzel J; Cicha I; Alexiou C
Anticancer Res; 2015 Nov; 35(11):5717-35. PubMed ID: 26503993
[TBL] [Abstract][Full Text] [Related]
22. Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX.
Harding-Jackson N; Sangueza M; Mackinnon A; Suster S; Plaza JA
Am J Dermatopathol; 2015 Jul; 37(7):509-14; quiz 515-6. PubMed ID: 26098709
[TBL] [Abstract][Full Text] [Related]
23. The role of CD10 in distinguishing atypical fibroxanthoma from sarcomatoid (spindle cell) squamous cell carcinoma.
Wieland CN; Dyck R; Weenig RH; Comfere NI
J Cutan Pathol; 2011 Nov; 38(11):884-8. PubMed ID: 21883368
[TBL] [Abstract][Full Text] [Related]
24. Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin.
Thum C; Hollowood K; Birch J; Goodlad JR; Brenn T
J Cutan Pathol; 2011 Dec; 38(12):954-60. PubMed ID: 22050092
[TBL] [Abstract][Full Text] [Related]
25. The many faces of Atypical fibroxanthoma.
Agaimy A
Semin Diagn Pathol; 2023 Jul; 40(4):306-312. PubMed ID: 37438163
[TBL] [Abstract][Full Text] [Related]
26. Pleomorphic Dermal Sarcoma.
Saleh JS; Whittington CP; Bresler SC; Patel RM
Surg Pathol Clin; 2024 Mar; 17(1):153-158. PubMed ID: 38278604
[TBL] [Abstract][Full Text] [Related]
27. Keloidal atypical fibroxanthoma: a case series.
Kim J; McNiff JM
J Cutan Pathol; 2009 May; 36(5):535-9. PubMed ID: 19476521
[TBL] [Abstract][Full Text] [Related]
28. CD163 is not a sensitive marker for identification of atypical fibroxanthoma.
Beer TW
J Cutan Pathol; 2012 Jan; 39(1):29-32. PubMed ID: 22211334
[TBL] [Abstract][Full Text] [Related]
29. CD117 is not a useful marker for diagnosing atypical fibroxanthoma.
Beer TW; Haig D
Am J Dermatopathol; 2009 Oct; 31(7):649-52. PubMed ID: 19652583
[TBL] [Abstract][Full Text] [Related]
30. Immunoexpression of ultraviolet photoproducts and p53 mutation analysis in atypical fibroxanthoma and superficial malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Itakura E; Oshiro Y; Nikaido O; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2001 Jun; 14(6):581-8. PubMed ID: 11406660
[TBL] [Abstract][Full Text] [Related]
31. Study of Epithelial to Mesenchymal Transition in Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma to Discern an Epithelial Origin.
Toll A; Gimeno J; Baró T; Hernández-Muñoz MI; Pujol RM
Am J Dermatopathol; 2016 Apr; 38(4):270-7. PubMed ID: 26999338
[TBL] [Abstract][Full Text] [Related]
32. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma.
Mihic-Probst D; Zhao J; Saremaslani P; Baer A; Oehlschlegel C; Paredes B; Komminoth P; Heitz PU
Anticancer Res; 2004; 24(1):19-26. PubMed ID: 15015571
[TBL] [Abstract][Full Text] [Related]
33. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers.
Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A
J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137
[TBL] [Abstract][Full Text] [Related]
34. CD117 immunoreactivity in atypical fibroxanthoma.
Mathew RA; Schlauder SM; Calder KB; Morgan MB
Am J Dermatopathol; 2008 Feb; 30(1):34-6. PubMed ID: 18212542
[TBL] [Abstract][Full Text] [Related]
35. Atypical Fibroxanthoma.
Chapman LW; Yu SS; Arron ST
Semin Cutan Med Surg; 2019 Mar; 38(1):E65-E66. PubMed ID: 31051027
[TBL] [Abstract][Full Text] [Related]
36. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
[TBL] [Abstract][Full Text] [Related]
37. CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.
Clarke LE; Frauenhoffer E; Fox E; Neves R; Bruggeman RD; Helm KF
J Cutan Pathol; 2010 Jul; 37(7):737-43. PubMed ID: 20175824
[TBL] [Abstract][Full Text] [Related]
38. Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management.
Soleymani T; Aasi SZ; Novoa R; Hollmig ST
Dermatol Clin; 2019 Jul; 37(3):253-259. PubMed ID: 31084719
[TBL] [Abstract][Full Text] [Related]
39. Atypical fibroxanthoma and pleomorphic dermal sarcoma - gene expression analysis compared with undifferentiated cutaneous squamous cell carcinoma.
Anders IM; Schimmelpfennig C; Wiedemann K; Löffler D; Kämpf C; Blumert C; Reiche K; Kunz M; Anderegg U; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2023 May; 21(5):482-491. PubMed ID: 37035902
[TBL] [Abstract][Full Text] [Related]
40. Atypical fibroxanthoma: new insights.
Hussein MR
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1075-88. PubMed ID: 24958232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
